Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-nectin-4/MMAE antibody-drug conjugate CRB-701

An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4), site-specifically conjugated, via a cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of anti-nectin-4/MMAE ADC CRB-701, the anti-nectin-4 antibody moiety targets and binds to nectin-4 expressed on tumor cells. Upon binding, internalization, and linker cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4-expressing tumor cells. Nectin-4, a TAA belonging to the nectin family, is overexpressed in a variety of cancers, but has a restricted distribution in normal tissue. CRB-701 may also induce anti-tumor activity through the induction of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against nectin-4-expressing tumor cells.
Synonym:ADC CRB-701
anti-nectin-4 ADC CRB-701
anti-nectin-4/MMAE ADC CRB-701
anti-nectin-4/MMAE ADC SYS6002
anti-nectin-4/MMAE antibody-drug conjugate SYS6002
Code name:CRB 701
CRB-701
CRB701
SYS 6002
SYS-6002
SYS6002
Search NCI's Drug Dictionary